WAM
APLS

Wolverine Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Wolverine Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-949
Closed -$27.4K – 1618
2024
Q3 		$27.4K Buy
+949
New +$35.1K ﹤0.01% 1240
2023
Q4 		– Sell
-6,100
Closed -$309K – 1786
2023
Q3 		$232K Buy
+6,100
New +$268K ﹤0.01% 1034

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Wolverine Asset Management's APLS Position: Q4 2024 in Review

Wolverine Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 949 shares — an estimated $27.4K sold.

Wolverine Asset Management first reported a position in APLS in Q3 2023 and held it in 2 quarters. The position peaked at $232K in Q3 2023. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • Wolverine Asset Management reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Wolverine Asset Management sold 949 Apellis Pharmaceuticals shares in Q4 2024, an estimated $27.4K.
  • Wolverine Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Wolverine Asset Management's Apellis Pharmaceuticals position peaked at $232K in Q3 2023.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on Wolverine Asset Management's 13F filing for Q4 2024, filed 3 Feb 2025.